10 results
P
Monte Carlo simulations
I/C
meta-analytical approaches, continuity correction methods, fixed effects, random effects
O
postoperative risk results, MSE values, effect of treatment, variance values between studies
P
South Africa, India, Turkey, Pakistan, Canada, Hong Kong, China
I/C
α-HCH, β-HCH, γ-HCH, ∑-HCH, Heptachlor, Aldrin, p,p'-DDE, p,p'-DDT, ∑-DDT, ∑-OCP, Surface water, Drinking water, Seawater, Groundwater
O
Concentration and prevalence of POPs, Carcinogenic risk, Non-carcinogenic risk
P
ONCOLOGY
I/C
DRUG, COMBINATION, PREVIOUSLY
O
SAFETY, DOSE-TOXICITY RELATIONSHIP
P
functional constipation (FC)
I/C
acupuncture, sham acupuncture
O
complete spontaneous bowel movement (CSBM), spontaneous bowel movement, Bristol Stool Form Scale (BSFS), responder rate, safety evaluation (SE)
P
early-stage cervical cancer
I/C
preoperative conization, radical hysterectomy with preoperative conization (CO) vs radical hysterectomy without preoperative conization (NCO)
O
disease-free survival outcomes
P
sheep, cattle
I/C
gamithromycin, lincomycin, oxytetracycline, erythromycin, amoxicillin, enrofloxacin, gamithromycin vs. amoxicillin, gamithromycin vs. enrofloxacin, lincomycin vs. oxytetracycline, erythromycin vs. oxytetracycline
O
curing rate
P
adult ED patients with severe agitation
I/C
ketamine, droperidol-midazolam, randomized controlled trials that enrolled adult ED patients with severe agitation and compared drugs for rapid tranquilization
O
Adequate sedation within 30 min (effectiveness), Immediate, serious adverse event - cardiac arrest, ventricular tachydysrhythmia, endotracheal intubation, laryngospasm, hypoxemia, hypotension (safety), Time to adequate sedation (effect onset)
P
patients undergoing colorectal surgery
I/C
early feeding, epidural analgesia, gastrograffin, nasogastric tube insertion, nasointestinal tube insertion, probiotics, acupuncture, no treatment, no intervention
O
time to solid diet tolerance, length of hospital stay, time to flatus, time to stool, requirement for post-operative nasogastric tube insertion
P
South Africa
I/C
Low-density lipoprotein cholesterol (LDL-C), theoretical minimum risk exposure level (TMREL)
O
attributable deaths, years of life lost, years lived with disability and disability-adjusted life years (DALYs)
P
advanced melanoma patients
I/C
immune checkpoint inhibitors (ICIs), ipilimumab, nivolumab, pembrolizumab, chemotherapy drugs (eg, dacarbazine, carboplatin, and paclitaxel)
O
cumulative incidence of any irAEs (regardless of severity), severe irAEs (grades 3-5)